The standardized mortality ratio (SMR) for systemic lupus erythematosus (SLE) is three; SMR increases to six in case of renal involvement. Up to now data on survival in case of neuropsychiatric involvement in SLE (NPSLE) have been scarce, therefore we calculated an SMR for NPSLE. Furthermore, we identified characteristics that influenced survival by Cox regression analyses. All patients suspected of NPSLE in our center since 1989 were evaluated and included in this study when a diagnosis of primary NPSLE could be established. Patient’s life/death status was tracked using the civic registries. Thirty-two (19%) of the 169 included NPSLE patients died within a median follow-up period of six years (range 0.5–24 years). This resulted in a significantly increased mortality rate compared to the general population: SMR 9.5 (95% CI 6.7–13.5). Hazard ratios (HRs) were highest in patients with acute confusional state (HR 3.4) and older age at diagnosis of NPSLE (HR 1.1). A decreased mortality risk was seen with the prescription of antiplatelet therapy (HR 0.22). The time period in which NPSLE was diagnosed did not significantly influence survival. Most frequent causes of death were infection and NPSLE itself.
MossKEIoannouYSultanSMHagIIsenbergDA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis2002; 61: 409–413.
2.
ReveilleJDBartolucciAAlarcónGS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum1990; 33: 37–48.
3.
UrowitzMBGladmanDDAbu-ShakraMFarewellVT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol1997; 24: 1061–1065.
4.
Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: A meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2013. doi: 10.1002/acr.22173 [Epub ahead of print].
5.
BernatskySBoivinJFJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
6.
NossentJCikesNKissE. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: Relation to disease activity and damage accrual. Lupus2007; 16: 309–317.
7.
AlarcónGSMcGwinGJrBastianHM. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum2001; 45: 191–202.
8.
Abu-ShakraMUrowitzMBGladmanDDGoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol1995; 22: 1265–1270.
9.
GinzlerEMDiamondHSWeinerM. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum1982; 25: 601–611.
10.
ChambersSAAllenERahmanAIsenbergD. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford)2009; 48: 673–675.
11.
LopezRDavidsonJEBeebyMDEggerPJIsenbergDA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford)2012; 51: 491–498.
12.
MakACheungMWChiewHJLiuYHoRC. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum2012; 41: 830–839.
13.
FunauchiMShimadzuHTamakiC. Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: Results from a single center. Rheumatol Int2007; 27: 243–249.
14.
UrowitzMBGladmanDD. Evolving spectrum of mortality and morbidity in SLE. Lupus1999; 8: 253–255.
15.
FaurschouMDreyerLKamperALStarklintHJacobsenS. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken)2010; 62: 873–880.
16.
YapDYTangCSMaMKLamMFChanTM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant2012; 27: 3248–3254.
17.
JönsenABengtssonAANivedORybergBSturfeltG. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology (Oxford)2002; 41: 1308–1312.
18.
MikdashiJHandwergerB. Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the Maryland lupus cohort. Rheumatology (Oxford)2004; 43: 1555–1560.
19.
TokanoYMorimotoSAmanoH. The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus. Mod Rheumatol2005; 15: 275–282.
20.
BernatskySClarkeAGladmanDD. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus2006; 15: 835–839.
21.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
22.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
23.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
24.
ZirkzeeEJSteup-BeekmanGMvan der MastRC. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol2012; 39: 2118–2126.
25.
Steup-BeekmanGMZirkzeeEJCohenD. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: Epidemiology and radiology pointing to an immune-mediated cause. Ann Rheum Dis2013; 72(Suppl 2): ii76–ii79.
26.
Statistics Netherlands 2012, statline.cbd.nl/statweb/ (accessed 1 September 2012).
27.
TherneauTMGrambschPM. Modeling survival data: Extending the Cox model, New York: Springer-Verlag New York Inc, 2012, pp. 261–287.
28.
GalliLSpagnuoloVSalpietroS. Mortality of HIV-infected patients with or without cancer: Comparison with the general population in Italy. Antivir Ther2012; 17: 447–458.
29.
ElhaiMMeuneCAvouacJKahanAAllanoreY. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology (Oxford)2012; 51: 1017–1026.
30.
SumelahtiMLHakamaMElovaaraIPukkalaE. Causes of death among patients with multiple sclerosis. Mult Scler2010; 16: 1437–1442.
31.
ChristiansenPBjerreKEjlertsenB. Mortality rates among early-stage hormone receptor-positive breast cancer patients: A population-based cohort study in Denmark. J Natl Cancer Inst2011; 103: 1363–1372.
32.
BertsiasGKIoannidisJPAringerM. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis2010; 69: 2074–2082.
33.
AudeYWMehtaJL. Nonplatelet-mediated effects of aspirin. Drugs Today (Barc)2002; 38: 501–507.
34.
Cohen D, Nabuurs RJ, Steup-Beekman GM, et al. Nationwide autopsy study links complement to thromboischemia in neurolupus (submitted for publication).
35.
CyrusTSungSZhaoLFunkCDTangSPraticòD. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation2002; 106: 1282–1287.
36.
McQuaidKRLaineL. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med2006; 119: 624–638.
